SHE Stock Overview
Through its subsidiaries, engages in the research, formulation, development, and marketing of nutraceuticals, dermocosmetics, medical devices, and pharmaceutical products in Italy.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Shedir Pharma Group S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.96 |
| 52 Week High | €4.68 |
| 52 Week Low | €3.34 |
| Beta | 0.75 |
| 11 Month Change | 4.21% |
| 3 Month Change | 4.76% |
| 1 Year Change | -13.54% |
| 33 Year Change | -11.01% |
| 5 Year Change | -43.91% |
| Change since IPO | -43.10% |
Recent News & Updates
Recent updates
Shedir Pharma Group's (BIT:SHE) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 05
Why Shedir Pharma Group's (BIT:SHE) Earnings Are Better Than They Seem
Oct 05Is Shedir Pharma Group (BIT:SHE) Using Too Much Debt?
Apr 06What Type Of Returns Would Shedir Pharma Group's(BIT:SHE) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Dec 30
Shareholder Returns
| SHE | IT Pharmaceuticals | IT Market | |
|---|---|---|---|
| 7D | 2.6% | -2.0% | -0.9% |
| 1Y | -13.5% | 11.6% | 17.3% |
Return vs Industry: SHE underperformed the Italian Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: SHE underperformed the Italian Market which returned 17.3% over the past year.
Price Volatility
| SHE volatility | |
|---|---|
| SHE Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in IT Market | 7.0% |
| 10% least volatile stocks in IT Market | 2.4% |
Stable Share Price: SHE has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: SHE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 84 | Antonio Scala | www.shedirpharma.com |
Shedir Pharma Group S.p.A., through its subsidiaries, engages in the research, formulation, development, and marketing of nutraceuticals, dermocosmetics, medical devices, and pharmaceutical products in Italy. It provides products for andrological, cardiovascular, dermatological, hematological, energy, gastrointestinal, gynecological, metabolic, neurological, dental, ophthalmic, osteoarticular, otologic, respiratory, and trichological diseases. The company offers its products through a network of sales agents, wholesalers, and pharmacies.
Shedir Pharma Group S.p.A. Fundamentals Summary
| SHE fundamental statistics | |
|---|---|
| Market cap | €45.00m |
| Earnings (TTM) | €6.00m |
| Revenue (TTM) | €60.96m |
7.5x
P/E Ratio0.7x
P/S RatioIs SHE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SHE income statement (TTM) | |
|---|---|
| Revenue | €60.96m |
| Cost of Revenue | €42.05m |
| Gross Profit | €18.91m |
| Other Expenses | €12.91m |
| Earnings | €6.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.53 |
| Gross Margin | 31.02% |
| Net Profit Margin | 9.84% |
| Debt/Equity Ratio | 7.3% |
How did SHE perform over the long term?
See historical performance and comparison